10 active not recruiting. 10 Phase 3.
By phase and status
Follow Bendamustine: new trials by email Literature Review of Bendamustine trials Research Report on Bendamustine
Trials (filtered) newest first · largest first
All 10 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors
BGB-16673, Bendamustine, Rituximab - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Active not recruiting | 153 | 2025-05-29 | 2026-08-24 |
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
Epcoritamab, Prednisone, Rituximab - Follicular Lymphoma (FL) | Phase 3 | Active not recruiting | 1095 | 2024-02-05 | 2026-08-04 |
A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)
Nemtabrutinib, Fludarabine, Cyclophosphamide - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Active not recruiting | 300 | 2023-03-16 | 2026-03-16 |
Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma
Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine - Relapsed/Refractory Follicular Lymphoma | Phase 3 | Active not recruiting | 231 | 2022-09-22 | 2025-10-15 |
A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Pirtobrutinib, Bendamustine, Rituximab - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Active not recruiting | 282 | 2021-09-23 | 2026-09-25 |
Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Pirtobrutinib, Idelalisib, Bendamustine - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Active not recruiting | 238 | 2021-03-09 | 2026-04-24 |
A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation
zanubrutinib, bendamustine, rituximab - Mantle Cell Lymphoma; Non-Hodgkin Lymphoma | Phase 3 | Active not recruiting | 510 | 2019-08-20 | 2026-09-30 |
A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL
Zanubrutinib, Bendamustine, Rituximab - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Active not recruiting | 590 | 2017-10-31 | 2026-03-09 |
A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL
Acalabrutinib, Bendamustine, Rituximab - Lymphoma, Mantle Cell | Phase 3 | Active not recruiting | 635 | 2017-04-05 | 2026-10-08 |
A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
Acalabrutinib (ACP-196), Rituximab, Idelalisib - Chronic Lymphocytic Leukemia | Phase 3 | Active not recruiting | 310 | 2017-02-02 | 2026-10-23 |
Conditions studied
Leukemia, Lymphocytic, Chronic, B-Cell (6) · Lymphoma, Non-Hodgkin (5) · Hematologic Diseases (2) · Lymphoma (2) · Lymphoma, B-Cell (2) · Lymphoma, Follicular (2) · Lymphoma, Mantle-Cell (2) · Neoplasms (1)
Sponsors
Acerta Pharma BV (2) · BeOne Medicines (2) · Loxo Oncology, Inc. (2) · BeiGene (1) · Genmab (1) · Kite, A Gilead Company (1) · Merck Sharp & Dohme LLC (1)
Countries
Taiwan (9) · United States (9) · Australia (8) · China (8) · France (8) · Italy (8) · Poland (8) · Spain (8) · United Kingdom (7) · Belgium (6) · Czechia (6) · Germany (6) · Hungary (6) · Japan (6) · New Zealand (6)
Top investigators
Marisa Hill, MD (1)
Results publications
PMID 31875923, PMID 32459600, PMID 32985902, PMID 33054121, PMID 33709202, PMID 35810754, PMID 37752878, PMID 38502198, PMID 38598745, PMID 39647999, PMID 40311141, PMID 40448577, PMID 40479620, PMID 40944848, PMID 41363770, PMID 41363773, PMID 41749915, PMID 42329537
NIH funding
2023 (3), 2015 (2), 2017 (1), 2019 (1)